Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

nenurodyta - Žmogaus normalusis imunoglobulinas - injekcinis tirpalas - 165 mg/ml - immunoglobulins, normal human, for extravascular adm.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sanofi pasteur - inaktyvuotas pasiutligės virusas wistar rabies pm/wi 38-1503-3m padermės - milteliai ir tirpiklis injekcinei suspensijai - 3,25 tv/0,5 ml; >=2,5 tv/0,5 ml - rabies, inactivated, whole virus

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - imunosupresantai - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocitopenija, idiopatinė - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ir 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ir 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

dyntec spol. s r. o. (Čekija) - injekcinė suspensija - 1 ml suspensijos yra: veikliųjų medžiagų: imunoglobulino nuo šunų maro nlt 160 vnab50⃰, imunoglobulino nuo šunų infekcinio laringotracheito ir infekcinio hepatito nlt 160 vnab50⃰, imunoglobulino nuo šunų parvovirusinio enterito nlt 1024 hiu⃰ ⃰⃰, imunoglobulino nuo šunų paragripo nlt 64 hiu⃰ ⃰; ⃰ virusus neutralizuojančių antikūnų titras pavyzdyje, kai sudavus vienkartinę dozę 50 % viruso iššauktų citopatinių pakitimų yra neutralizuojami. ⃰ ⃰ virusų hemagliutinaciją stabdantis antikūnų titras pavyzdyje, kai sudavus vienkartinę dozę pasireiškia 50 % hemagliutinizacijos atvejų. - pasyviai šunų imunizacijai nuo maro, infekcinio hepatito, šunų infekcinio laringotracheito, parvovirusinio enterito ir šunų paragripo.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novartis europharm limited - omalizumabas - asthma; urticaria - vaistai nuo obstrukcinių kvėpavimo takų ligų, - alerginės asthmaxolair yra nurodyta suaugusiems, paaugliams ir vaikams (nuo 6 iki.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

dyntec spol. s r. o. (Čekija) - injekcinė suspensija - 1 ml suspensijos yra: imunoglobulino nuo šunų parvovirusinio enterito - nlt 1024 hiu ⃰; ⃰ virusų hemagliutinaciją stabdantis antikūnų titras pavyzdyje, kai sudavus vienkartinę dozę pasireiškia 50 % hemagliutinizacijos atvejų. - pasyviai šunų imunizacijai nuo parvovirusinio enterito.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

dyntec spol. s r. o. (Čekija) - injekcinė suspensija - antidepressants names buy antidepressants uk adamsescapades.com antidepressants1 ml suspensijos yra: imunoglobulino nuo šunų maro - nlt 320 vnab50⃰ ; ⃰ virusus neutralizuojančių antikūnų titras pavyzdyje, kai sudavus vienkartinę dozę 50 % viruso iššauktų citopatinių pakitimų yra neutralizuojami. - pasyviai šunų imunizacijai nuo maro.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - kiti antineoplastiniai agentai - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumabas - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antinavikiniai vaistai - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. daugiau informacijos apie žmogaus epidermio augimo faktoriaus receptorių 2 (her2) būklę rasite 5 skyriuje. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. daugiau informacijos apie her2 statusą rasite 5 skyriuje. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.